Santhera, Valeant Pharmaceuticals deal

Valeant returned U.S. and Canadian rights to Santhera for fipamezole ( JP-1730). Valeant gained rights to the program through its merger with Biovail Corp. this year, but decided not to continue the project after a review of the merged company's pipelines, according to Santhera (see BioCentury, Oct. 4). ...